Cellectis S.A. (EPA:ALCLS) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Shareholders might have noticed that Cellectis S.A. (EPA:ALCLS) filed its quarterly result this time last week. The early response was not positive, with shares down 2.4% to €2.41 in the past week. It was a weak result overall, with Cellectis reporting US$6.8m in revenues, which was 37% less than what the analysts had expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Cellectis after the latest results.
After the latest results, the consensus from Cellectis' four analysts is for revenues of US$51.8m in 2026, which would reflect a not inconsiderable 19% decline in revenue compared to the last year of performance. The loss per share is expected to ameliorate slightly, reducing to US$0.87. Before this earnings announcement, the analysts had been modelling revenues of US$58.3m and losses of US$0.85 per share in 2026. So there's been quite a change-up of views after the recent consensus updates, withthe analysts making a serious cut to their revenue outlook while also expecting losses per share to increase.
See our latest analysis for Cellectis
The consensus price target fell 59% to €6.50, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We would highlight that revenue is expected to reverse, with a forecast 34% annualised decline to the end of 2026. That is a notable change from historical growth of 21% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 55% per year. It's pretty clear that Cellectis' revenues are expected to perform substantially worse than the wider industry.
The Bottom Line
The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Cellectis. Unfortunately, they also downgraded their revenue estimates, and our data indicates underperformance compared to the wider industry. Even so, earnings per share are more important to the intrinsic value of the business. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Cellectis analysts - going out to 2028, and you can see them free on our platform here.
We don't want to rain on the parade too much, but we did also find 4 warning signs for Cellectis (2 are a bit unpleasant!) that you need to be mindful of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.